Faraday Pharmaceuticals is focused on developing innovative therapies to address critical health issues, particularly in the realm of cardiovascular diseases. Their lead investigational product, FDY-5301, is a formulation of sodium iodide designed to mitigate ischemia-reperfusion injury (IRI) that occurs during myocardial infarction (MI). This product has demonstrated the ability to neutralize harmful hydrogen peroxide produced during IRI, thereby reducing tissue damage, inflammation, and infarct size in preclinical models. The company aims to complement existing treatments, such as percutaneous coronary intervention (PCI), by providing a novel approach to protect patients from the adverse effects of heart attacks.

The mechanism of action for FDY-5301 involves enhancing the body's natural response to stress by significantly increasing blood iodide levels, which catalytically destroys hydrogen peroxide and modulates inflammatory pathways. This multi-faceted strategy not only reduces reactive oxygen species (ROS) damage but also limits neutrophil migration into affected tissues, thereby addressing multiple pathways that contribute to IRI. Currently, FDY-5301 is undergoing evaluation in a Phase 3 clinical trial (Iocyte AMI-3) to assess its efficacy in reducing heart failure and cardiovascular death among patients suffering from anterior STEMI, highlighting its potential as a first-in-class intervention in this critical area of healthcare.

United States

At Faraday Pharmaceuticals, Inc., our mission is to improve quality of life for patients after acute critical illness by minimizing damage to cardiac and skeletal muscle.


Faraday Pharmaceuticals

Company Details